Your Privacy Matters

Parts of this website use cookies and content from third-party providers. More details can be read in our privacy policy, which also describes how you can amend your preferences at any time.

 Skip to main content
Cover of the nVentic Big Pharma inventory trends benchmarking report 2026

Download your copy

Thank you for your interest in nVentic’s 2026 Big Pharma inventory trends benchmark. Your report is ready.

Download the PDF

The report opens in a new tab. You can save it from your browser’s PDF viewer.

Inside the report

  • See how combined inventories across 28 benchmarked pharmaceutical companies rose to $170bn in fiscal 2025.
  • Compare large pharma, where median DIO rose by 25 days, with the regular pharma group, where median DIO fell by 24 days.
  • Understand the GLP-1 launch effect, acquisition impacts and planning dynamics behind the sharpest DIO movements.

Would you like to discuss the findings?

Talk to nVentic about what the benchmark could mean for your inventory strategy and working capital.

Contact nVentic